Myeloma Canada | Research & Access Updates

— Monday, May 31, 2021

Health Canada Approves ABECMA (idecabtagene vicleucel), the First and Only Anti-BCMA CAR T cell Therapy for Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb Canada (BMS) today announced Health Canada has granted conditional approval (NOC/c)...

— Friday, May 28, 2021

A summary safety review (SSR) regarding Pomalyst (pomalidomide) and Thalomid (thalidomide) and the poten...

— Thursday, March 18, 2021

The Canadian Cancer Trials Group (CCTG) and Queen’s researcher Annette Hay (Medicine) and Jonathan Bramso...

— Friday, February 19, 2021

This year, for the first time, the publication of the annual Cancer System Quality Index by Cancer Care O...

— Wednesday, February 17, 2021

(Toronto, Ont.) January 27, 2021 ¬– FORUS Therapeutics launches today, bringing a new pharmaceutical comp...

— Tuesday, February 16, 2021

Farmers have a higher incidence of multiple myeloma, and there is suggestive evidence of an elevated prev...